These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11009708)

  • 41. When a long shot is worth a shot.
    Jacobs T; Fischer J
    Nat Biotechnol; 2005 Jul; 23(7):805. PubMed ID: 16003361
    [No Abstract]   [Full Text] [Related]  

  • 42. Spinning the wheel on ImClone.
    Varchaver N
    Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
    [No Abstract]   [Full Text] [Related]  

  • 43. Biotech plummets in 3Q11.
    Yang W
    Nat Biotechnol; 2011 Nov; 29(11):962. PubMed ID: 22068525
    [No Abstract]   [Full Text] [Related]  

  • 44. Changing partners.
    Nat Biotechnol; 2002 Sep; 20(9):855. PubMed ID: 12205487
    [No Abstract]   [Full Text] [Related]  

  • 45. Swooping for biotech.
    Wadman M
    Nature; 2005 Sep; 437(7058):475. PubMed ID: 16177760
    [No Abstract]   [Full Text] [Related]  

  • 46. Profit at a cost?
    Nat Cell Biol; 2000 Jul; 2(7):E113. PubMed ID: 10878816
    [No Abstract]   [Full Text] [Related]  

  • 47. Biotech at the beauty counter.
    Nasto B
    Nat Biotechnol; 2007 Jun; 25(6):617-9. PubMed ID: 17557090
    [No Abstract]   [Full Text] [Related]  

  • 48. HGS drug flop latest genomics setback.
    Reid B
    Nat Biotechnol; 2002 Jun; 20(6):533. PubMed ID: 12042841
    [No Abstract]   [Full Text] [Related]  

  • 49. Niche indications could drive higher valuations.
    Ransom J
    Nat Biotechnol; 2006 Dec; 24(12):1457. PubMed ID: 17160028
    [No Abstract]   [Full Text] [Related]  

  • 50. Sanofi Aventis grooms its ranks for biotech partnering.
    Moran N
    Nat Biotechnol; 2009 Jul; 27(7):581-2. PubMed ID: 19587645
    [No Abstract]   [Full Text] [Related]  

  • 51. What does the current biotech stock market value?
    McNamee L; Ledley F
    Nat Biotechnol; 2015 Aug; 33(8):813-4. PubMed ID: 26252135
    [No Abstract]   [Full Text] [Related]  

  • 52. Biotechnology in the Medicon Valley.
    Frank L
    Nature; 2002 Dec; 420(6916 Suppl):A27, A29, A31 passim. PubMed ID: 12501124
    [No Abstract]   [Full Text] [Related]  

  • 53. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 54. More than meets the eyes?
    Jacobs T
    Nat Biotechnol; 2004 Oct; 22(10):1221. PubMed ID: 15470455
    [No Abstract]   [Full Text] [Related]  

  • 55. No pain, no gain?
    Jacobs T
    Nat Biotechnol; 2005 Aug; 23(8):934. PubMed ID: 16082357
    [No Abstract]   [Full Text] [Related]  

  • 56. Great company, bad stock.
    Jacobs T
    Nat Biotechnol; 2005 Feb; 23(2):173. PubMed ID: 15696142
    [No Abstract]   [Full Text] [Related]  

  • 57. Eli Lilly enters venture capital arena.
    Fletcher L
    Nat Biotechnol; 2001 Nov; 19(11):997-8. PubMed ID: 11689830
    [No Abstract]   [Full Text] [Related]  

  • 58. The biotech drug market.
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
    [No Abstract]   [Full Text] [Related]  

  • 59. Today's biotech industry in India.
    Suresh N
    Biotechnol J; 2009 Mar; 4(3):291-4. PubMed ID: 19296434
    [No Abstract]   [Full Text] [Related]  

  • 60. IPO floodgates unlikely to open after Ark floatation.
    Louët S
    Nat Biotechnol; 2004 Apr; 22(4):367-8. PubMed ID: 15060538
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.